Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28604701.
- Also identified by DOI 10.1038/nm.4356.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The potential of bispecific T cell-engaging antibodies is hindered by manufacturing challenges and short serum half-life. We circumvented these limitations by treating mice with in vitro-transcribed pharmacologically optimized, nucleoside-modified mRNA encoding the antibody. We achieved sustained endogenous synthesis of the antibody, which eliminated advanced tumors as effectively as the corresponding purified bispecific antibody. Because manufacturing of pharmaceutical mRNA is fast, this approach could accelerate the clinical development of novel bispecific antibodies.
Medical subject headings
- Antibodies, Bispecific
- Cytokines
- Neoplasms
- RNA, Messenger
- T-Lymphocytes
- Tumor Burden